Dermacyte Matrix
Advanced Wound Care
CommercialActive
Key Facts
About Merakris Therapeutics
Merakris Therapeutics, founded in 2015 and based in Durham, NC, is an emerging leader in regenerative medicine with a unique focus on cell-free therapeutics. The company leverages cell-derived proteins and extracellular matrix technology to develop products for advanced wound care and ophthalmology. Its lead investigational drug, MTX-001, is in clinical development following positive FDA interactions, positioning Merakris to address significant unmet needs in chronic wound healing. The company operates as a private, science-led organization advancing both commercial products and a robust clinical pipeline.
View full company profileTherapeutic Areas
Other Advanced Wound Care Drugs
| Drug | Company | Phase |
|---|---|---|
| Microcyn®/Oxum® (Rx) | Sonoma Pharmaceuticals | Commercial |
| XLR8+ Multi-Level Intensity | Genadyne Biotechnologies | Commercial |
| NovaForm Wound Matrix Distribution | NovaBone | Commercial |
| Nexodyn® AOS | APR Applied Pharma Research | Marketed |
| Hydrofiber® EVOLUTION | ConvaTec | Commercial |